Drug-grapefruit juice interactions

Garvan M Kane, James J. Lipsky

Research output: Contribution to journalArticle

258 Citations (Scopus)

Abstract

Grapefruit juice, a beverage consumed in large quantities by the general population, is an inhibitor of the intestinal cytochrome P-450 3A4 system, which is responsible for the first-pass metabolism of many medications. Through the inhibition of this enzyme system, grapefruit juice interacts with a variety of medications, leading to elevation of their serum concentrations. Most notable are its effects on cyclosporine, some 1,4-dihydropyridine calcium antagonists, and some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. In the case of some drugs, these increased drug concentrations have been associated with an increased frequency of dose-dependent adverse effects. The P-glycoprotein pump, located in the brush border of the intestinal wall, also transports many cytochrome P-450 3A4, substrates, and this transporter also may be affected by grapefruit juice. This review discusses the proposed mechanisms of action and the medications involved in drug-grapefruit juice interactions and addresses the clinical implications of these interactions.

Original languageEnglish (US)
Pages (from-to)933-942
Number of pages10
JournalMayo Clinic Proceedings
Volume75
Issue number9
StatePublished - 2000

Fingerprint

Citrus paradisi
Pharmaceutical Preparations
Beverages
P-Glycoprotein
Microvilli
Cytochrome P-450 Enzyme System
Cyclosporine
Oxidoreductases
Calcium
Enzymes
Serum
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kane, G. M., & Lipsky, J. J. (2000). Drug-grapefruit juice interactions. Mayo Clinic Proceedings, 75(9), 933-942.

Drug-grapefruit juice interactions. / Kane, Garvan M; Lipsky, James J.

In: Mayo Clinic Proceedings, Vol. 75, No. 9, 2000, p. 933-942.

Research output: Contribution to journalArticle

Kane, GM & Lipsky, JJ 2000, 'Drug-grapefruit juice interactions', Mayo Clinic Proceedings, vol. 75, no. 9, pp. 933-942.
Kane, Garvan M ; Lipsky, James J. / Drug-grapefruit juice interactions. In: Mayo Clinic Proceedings. 2000 ; Vol. 75, No. 9. pp. 933-942.
@article{8f417256771b4549868d3262a14c5ae7,
title = "Drug-grapefruit juice interactions",
abstract = "Grapefruit juice, a beverage consumed in large quantities by the general population, is an inhibitor of the intestinal cytochrome P-450 3A4 system, which is responsible for the first-pass metabolism of many medications. Through the inhibition of this enzyme system, grapefruit juice interacts with a variety of medications, leading to elevation of their serum concentrations. Most notable are its effects on cyclosporine, some 1,4-dihydropyridine calcium antagonists, and some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. In the case of some drugs, these increased drug concentrations have been associated with an increased frequency of dose-dependent adverse effects. The P-glycoprotein pump, located in the brush border of the intestinal wall, also transports many cytochrome P-450 3A4, substrates, and this transporter also may be affected by grapefruit juice. This review discusses the proposed mechanisms of action and the medications involved in drug-grapefruit juice interactions and addresses the clinical implications of these interactions.",
author = "Kane, {Garvan M} and Lipsky, {James J.}",
year = "2000",
language = "English (US)",
volume = "75",
pages = "933--942",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Drug-grapefruit juice interactions

AU - Kane, Garvan M

AU - Lipsky, James J.

PY - 2000

Y1 - 2000

N2 - Grapefruit juice, a beverage consumed in large quantities by the general population, is an inhibitor of the intestinal cytochrome P-450 3A4 system, which is responsible for the first-pass metabolism of many medications. Through the inhibition of this enzyme system, grapefruit juice interacts with a variety of medications, leading to elevation of their serum concentrations. Most notable are its effects on cyclosporine, some 1,4-dihydropyridine calcium antagonists, and some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. In the case of some drugs, these increased drug concentrations have been associated with an increased frequency of dose-dependent adverse effects. The P-glycoprotein pump, located in the brush border of the intestinal wall, also transports many cytochrome P-450 3A4, substrates, and this transporter also may be affected by grapefruit juice. This review discusses the proposed mechanisms of action and the medications involved in drug-grapefruit juice interactions and addresses the clinical implications of these interactions.

AB - Grapefruit juice, a beverage consumed in large quantities by the general population, is an inhibitor of the intestinal cytochrome P-450 3A4 system, which is responsible for the first-pass metabolism of many medications. Through the inhibition of this enzyme system, grapefruit juice interacts with a variety of medications, leading to elevation of their serum concentrations. Most notable are its effects on cyclosporine, some 1,4-dihydropyridine calcium antagonists, and some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. In the case of some drugs, these increased drug concentrations have been associated with an increased frequency of dose-dependent adverse effects. The P-glycoprotein pump, located in the brush border of the intestinal wall, also transports many cytochrome P-450 3A4, substrates, and this transporter also may be affected by grapefruit juice. This review discusses the proposed mechanisms of action and the medications involved in drug-grapefruit juice interactions and addresses the clinical implications of these interactions.

UR - http://www.scopus.com/inward/record.url?scp=0033831256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033831256&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 933

EP - 942

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -